KURA ONCOLOGY INC (KURA)
Health Care · biotechnology · NASDAQ
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
What KURA ONCOLOGY INC does
Kura Oncology is a clinical-stage biopharmaceutical company developing and commercializing oncology therapies. The company has commercialized KOMZIFTI (tipifarnib), an oral farnesyltransferase inhibitor, and maintains a pipeline of product candidates in development. Kura generates revenue from product sales and collaboration agreements, including a license agreement with Kyowa Kirin for development and commercialization rights.
Themes: precision medicine, oncology, targeted cancer therapy, menin inhibition, hematologic malignancies
Fundamentals
- Price$11.89 as of 2026-08-21 close
- Market cap$1.1B as of 2026-08-21
- 1-year return+59.8% 2025-08-21 close $7.44 → 2026-08-21 close $11.89
- P/En/a negative earnings
- Net margin-411.2% as of 2026-08-24
- Gross margin+99.9% as of 2026-08-24
- ROE-141.9% as of 2026-08-24
- Debt / equity0.09 as of 2026-08-24
- Revenue growth (YoY)+29.5% as of 2026-08-24
- Beta0.43 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How KURA compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How KURA ONCOLOGY INC looks technically
KURA ONCOLOGY INC (KURA) is trading 22.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 44 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 22.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.47 | $10.47 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.69 | $9.69 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 43 calendar days ago — the swings before that are what the structure reading is measured on | 43 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 44 trading days ago — a "golden cross", a bullish long-term signal | 44 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 22.7% above | +22.7% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with buyers in control | 26.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 63.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($9.11 to $12.90) — its "stochastic" reading is 73 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 73.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $12.90 | $12.90 |
|---|---|---|
| From the 52-week high | it is 7.8% below its 52-week high (its highest price of the past year) | -7.8% |
| Above the 52-week low | it is 71.1% above its 52-week low (its lowest price of the past year) | +71.1% |
| Below the 52-week high | it is 7.8% below its highest point of the past year | 7.8% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $43.00 (set on 2020-12-09) | $43.00 |
| Given back of the 52-week move | over the past year its closes ranged ($7.05 to $12.53), and it has given back only a small part of its rise from last year’s low — 12% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.97 to $9.14. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 11.7% |
| From the all-time high | it is 72.3% below its all-time high | -72.3% |
| Nearest price level | it is trading 2.7% above a support level at $11.57 — a price it turned at twice since 2024-12-02, most recently on 2026-05-22. Since 2024-08-21 it has 9 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.7% |
| All-time low | its lowest closing price on record is $2.50 (set on 2016-07-05) | $2.50 |
| Above the all-time low | it is 375.6% above its all-time low | +375.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6492 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6492 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $7.94 and $12.44 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $7.94 – $10.19 – $12.44 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges above its 200-day average price (22.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.31× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.7% since the prior reading | +2.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.6% |
|---|---|---|
| Open gap | it gapped 6.3% above the previous close 3 sessions ago and has not traded back through the level it left behind at 11.28 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.3% |
| Gap filled | a 3.2% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 6.9 percentage points (the stock gained 9.2% while the market gained 2.3%) | +6.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.7 percentage points (the stock gained 6.8% while the market gained 3.1%) | +3.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 29.5 percentage points (the stock gained 40.5% while the market gained 11.1%) | +29.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 39.3 percentage points (the stock gained 59.8% while the market gained 20.5%) | +39.3% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.2% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.9% of the share price. | +9.2% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 24% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.58 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +24.1% |
|---|
Price levels it has turned at before
KURA last closed at $11.89 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.57 | Support | 2.7% below the last close | turned there twice · 2024-12-02 to 2026-05-22 |
| $12.27 | Resistance | 3.2% above the last close | turned there twice · 2025-12-04 to 2026-07-09 |
| $9.65 | Support | 18.8% below the last close | turned there three times · 2024-11-21 to 2026-03-10 |
| $9.12 | Support | 23.3% below the last close | turned there twice · 2025-02-05 to 2025-10-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$32.00 range $15.00 – $76.00; median $28.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KURA
- Consensus EPS estimate-$0.8067 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on successful commercialization of KOMZIFTI; limited market acceptance or uptake could significantly impact revenues and financial viability","Competition from established and emerging oncology therapies; success of competing drugs could erode market share and pricing","Regulatory risk; loss of regulatory approval, product holds, or label restrictions for KOMZIFTI or pipeline candidates could impair commercialization and revenue generation"]
What changed in the latest 10-Q
AI-assisted comparison of KURA's 10-Q filed 2026-05-12 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- FDA approved NDA for ziftomenib (KOMZIFTI) on November 13, 2025
- KOMZIFTI is marketed in the United States for relapsed/refractory AML with NPM1 mutation
- KOMZIFTI is the first and only menin inhibitor approved for once-daily oral administration
- Commercial sales of KOMZIFTI initiated in the United States on November 21, 2025
- Detailed efficacy data: CR+CRh rate of 21.4% (95% CI: 14.2, 30.2), median duration of CR+CRh five months, median time to first response 2.7 months
- 88% of patients achieving CR or CRh did so within six months
- Detailed safety profile listing specific adverse events reported in 20% or more of patients
- No Grade 4 or Grade 5 QTc interval prolongation reported
- 12% of patients experienced QTc interval prolongation of ≤ Grade 3
- Of 70 patients 65 years or older, 10% experienced QTc interval prolongation
- KOMZIFTI includes Black Box warning for differentiation syndrome only, not for QTc prolongations
- KOMZIFTI can be co-administered without dose modification with CYP3A4 inhibitors or inducers
- Reference to Kyowa Co-Promotion Agreement entered into in June 2025
- Reference to full results published in Journal of Clinical Oncology in September 2025
- Removed:
- Description of Kura as 'clinical-stage biopharmaceutical company' (changed to 'fully-integrated commercial-stage organization')
- Statement about pairing product candidates with molecular or cellular diagnostics
- Description of ziftomenib as 'investigational inhibitor' and 'lead product candidate'
- Discussion of ziftomenib development for ALL (acute lymphoblastic leukemia)
- Discussion of ziftomenib in combination with imatinib for GIST treatment
- Discussion of ziftomenib and next-generation menin inhibitors for diabetes and cardiometabolic disorders
- Discussion of FTI programs (darlifarnib and tipifarnib)
- Discussion of discovery-stage programs
- Reference to March 31, 2025 NDA submission date
- Reference to June 1, 2025 FDA acceptance and Priority Review announcement
- Reference to PDUFA target action date of November 30, 2025
- Reference to September 25, 2025 Journal of Clinical Oncology publication details and Phase 2 data cutoff date of October 28, 2024
- Reworded:
- Reference to fiscal year ended December 31, 2025 (vs. 2024 in older filing)
- Reference to Annual Report on Form 10-K filed March 5, 2026 (vs. February 28, 2025)
- Changed from 'clinical-stage biopharmaceutical company' to 'biopharmaceutical company...transformed from a research and development company to a fully-integrated commercial-stage organization'
- Changed from describing ziftomenib as 'lead product candidate' to describing KOMZIFTI as approved product with commercial sales
- Changed from discussing development activities to discussing commercial-stage operations and market differentiation
- Notes:
- The newer filing appears to be cut off mid-sentence regarding the Kyowa Co-Promotion Agreement details
- Efficacy data percentages differ slightly between filings (21.4% vs. 22% CR+CRh rate), but this may reflect different populations or data cutoff dates
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($834283) — 1 selling insider
- Last 180 days0 buys · 5 sells ($989048) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KURA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding KURA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 16,546,767
- Reported value $134,525,217
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
KURA had 13,160,945 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KURA had 14.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.81 days to cover at the same settlement.
- Reported short interest (shares) 13,160,945
- Short interest (% of shares outstanding) 14.8%
- Prior settlement (shares) 13,732,567
- Reported change -4.16%
- Days to cover (reported) 11.81
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Syndax Pharmaceuticals (SNDX)
- Revolution Medicines (RVMD)
- Blueprint Medicines (BPMC)
- Gilead Sciences (GILD)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KURA vs…
KURA ONCOLOGY INC is found in…
Frequently asked questions
What does KURA ONCOLOGY INC (KURA) do?
Kura Oncology is a clinical-stage biopharmaceutical company developing and commercializing oncology therapies. The company has commercialized KOMZIFTI (tipifarnib), an oral farnesyltransferase inhibitor, and maintains a pipeline of product candidates in development. Kura generates revenue from product sales and collaboration agreements, including a license agreement with Kyowa Kirin for development and commercialization rights.
What sector is KURA ONCOLOGY INC (KURA) in?
KURA ONCOLOGY INC (KURA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are KURA ONCOLOGY INC's (KURA) competitors?
Notable peers of KURA ONCOLOGY INC (KURA) include Syndax Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Gilead Sciences and Novartis. This peer set is informational only — not financial advice.
Is KURA ONCOLOGY INC (KURA) overbought or oversold right now?
KURA ONCOLOGY INC (KURA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KURA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.